{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:28:28Z","timestamp":1769164108282,"version":"3.49.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER18A1"],"award-info":[{"award-number":["SANDER18A1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER20A0-AP"],"award-info":[{"award-number":["SANDER20A0-AP"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER18A1"],"award-info":[{"award-number":["SANDER18A1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["SANDER20A0-AP"],"award-info":[{"award-number":["SANDER20A0-AP"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Despite the high prevalence and clear morbidity of cystic fibrosis (CF) pulmonary exacerbations (PEx), there have been no published clinical trials of outpatient exacerbation management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the feasibility of a pediatric clinical trial in which treatment of mild PEx is assigned randomly to immediate oral antibiotics or tailored therapy (increased airway clearance alone with oral antibiotics added only for prespecified criteria). The outcome on which sample size was based was the proportion of tailored therapy participants who avoided oral antibiotics during the 28\u2009days after randomization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized, open-label, pilot feasibility study at 10\u2009U.S. sites, children 6\u201318\u2009years of age with CF were enrolled at their well baseline visits and followed through their first randomized PEx.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred twenty-one participants were enrolled, of whom 94 (78%) reported symptoms of PEx at least once; of these, 81 (86%) had at least one exacerbation that met randomization criteria, of whom 63 (78%) were randomized. Feasibility goals were met, including enrollment, early detection of symptoms of PEx, and ability to randomize. Among the 33 participants assigned to tailored therapy, 10 (30%) received oral antibiotics, while 29 of 30 (97%) assigned to immediate antibiotics received oral antibiotics. The avoidance of oral antibiotics in 70% (95% confidence interval, 54\u201385%) was statistically significantly different from our null hypothesis that &amp;lt;10% of participants assigned to the tailored therapy arm would avoid antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our pilot study demonstrates that conducting a randomized trial of oral antibiotic treatment strategies for mild PEx in children with CF is feasible and that assignment to a tailored therapy arm may reduce antibiotic exposure.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT 04608019).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202303-245oc","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T15:38:43Z","timestamp":1694187523000},"page":"1769-1776","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":11,"title":["A Pilot Randomized Clinical Trial of Pediatric Cystic Fibrosis Pulmonary Exacerbations Treatment Strategies"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-6249","authenticated-orcid":false,"given":"Don B.","family":"Sanders","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Traci M.","family":"Bartz","sequence":"additional","affiliation":[{"name":"Collaborative Health Studies Coordinating Center, Department of Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith T.","family":"Zemanick","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Colorado, Aurora, Colorado; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordana E.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Colorado, Aurora, Colorado; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen D.","family":"Hinckley Stukovsky","sequence":"additional","affiliation":[{"name":"Collaborative Health Studies Coordinating Center, Department of Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Cogen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Bendy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Indiana University, Indianapolis, Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"McNamara","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Enright","sequence":"additional","affiliation":[{"name":"Collaborative Health Studies Coordinating Center, Department of Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah A.","family":"Kime","sequence":"additional","affiliation":[{"name":"Collaborative Health Studies Coordinating Center, Department of Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Kronmal","sequence":"additional","affiliation":[{"name":"Collaborative Health Studies Coordinating Center, Department of Biostatistics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Health Systems and Population Health and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne J.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Arizona, Tucson, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Washington, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"2026012203293684700_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jpeds.2005.10.019","article-title":"Cystic fibrosis pulmonary exacerbations","volume":"148","author":"Ferkol","year":"2006","journal-title":"J Pediatr"},{"key":"2026012203293684700_bib2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ppul.22652","article-title":"Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis","volume":"48","author":"Wagener","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2026012203293684700_bib3","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/ppul.25092","article-title":"Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers","volume":"55","author":"Hoppe","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2026012203293684700_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcf.2019.06.008","article-title":"Predictors of pulmonary exacerbation treatment in cystic fibrosis","volume":"19","author":"Sanders","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026012203293684700_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"key":"2026012203293684700_bib6","first-page":"S422","article-title":"Pediatric pulmonary exacerbations: approach and research priorities of caregivers and CF center directors [abstract]","volume":"54","author":"Zemanick","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"2026012203293684700_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1513\/AnnalsATS.201802-149OC","article-title":"Longitudinal trends in real-world outcomes after initiation of ivacaftor: a cohort study from the Cystic Fibrosis Registry of Ireland","volume":"16","author":"Kirwan","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203293684700_bib8","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203293684700_bib9","first-page":"522","article-title":"Cystic fibrosis pulmonary guidelines: airway clearance therapies","volume":"54","author":"Flume","year":"2009","journal-title":"Respir Care"},{"key":"2026012203293684700_bib10","first-page":"A251","article-title":"Validation of a novel patient-reported respiratory symptoms instrument in cystic fibrosis: CFRSD-CRISS [abstract]","volume":"48","author":"Goss","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2026012203293684700_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S2213-2600(19)30254-1","article-title":"Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial","volume":"7","author":"Goyal","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2026012203293684700_bib12","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(18)31723-9","article-title":"Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial","volume":"392","author":"Goyal","year":"2018","journal-title":"Lancet"},{"key":"2026012203293684700_bib13","doi-asserted-by":"crossref","first-page":"e20201323","DOI":"10.1542\/peds.2020-1323","article-title":"Delayed antibiotic prescription for children with respiratory infections: a randomized trial","volume":"147","author":"Mas-Dalmau","year":"2021","journal-title":"Pediatrics"},{"key":"2026012203293684700_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/thoraxjnl-2016-208450","article-title":"Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis","volume":"72","author":"Stanojevic","year":"2017","journal-title":"Thorax"},{"key":"2026012203293684700_bib15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1513\/AnnalsATS.201401-034OI","article-title":"Is there a role for antimicrobial stewardship in cystic fibrosis?","volume":"11","author":"Waters","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203293684700_bib16","first-page":"S238","article-title":"FEV1 indicated exacerbation signal: a new CF registry metric to detect potential pulmonary exacerbations","volume":"54","author":"Petren","year":"2019","journal-title":"Pediatr Pulmonol"}],"updated-by":[{"DOI":"10.1513\/annalsats.21i7erratum","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000}}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/20\/12\/1769\/66267560\/annalsats_20_12_1769.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/20\/12\/1769\/66267560\/annalsats_20_12_1769.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:31:26Z","timestamp":1769070686000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/20\/12\/1769\/8414392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202303-245oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"2023-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}